Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Omalizumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 34 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab (ATC-Code nach WHO: R03DX05)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive pharmaceutical rebate agreement for medicines containing Omalizumab.
  • Open-house participation model with no individual negotiations.
Pokaż pełne podsumowanie

Open-house supply arrangement for the active substance Omalizumab (ATC R03DX05) with AOK PLUS. It is a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V, open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or delivery exclusivity apply. The notice states that quantities are unknown and minimum purchase volumes are not guaranteed. Participation documents are available via DTVP project space, but the extracted procurement documents were not provided for analysis.

Ryzyka

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Required documents explicitly mentioned: completed declaration of no exclusion grounds and declaration regarding Russia sanctions.

Administrative

  • Participation documents must be obtained via the DTVP project space after access approval.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Omalizumab

Non-exclusive supply arrangement for pharmaceutical products containing Omalizumab (ATC R03DX05). The lot is an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no guaranteed minimum quantities, and no individual contract negotiations are stated. Performance location is Dresden, Germany, with coverage indicated for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Sep 2025 - Sep 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
24 Aug 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
552774-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3